Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of recurrence, including liver (96%), lymph nodes (89%), abdominopelvic (86%) ...

SAN DIEGO and SUZHOU, China - Adagene Inc. (NASDAQ: ADAG), a biotechnology firm with a market capitalization of $85 million ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the ...

Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...

Adagene (ADAG) announced updated clinical data from ADG126 in microsatellite stable colorectal cancer, MSS CRC, at the ASCO Gastrointestinal ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of ...

Unintended consequences of halting vaccine research: more cancer deaths? by Wendy Sacks, CT Mirror <br />January 27, 2025 ...

Scientific Advisory Board formed with internationally recognized liver and biliary tract cancer physicians to support the advancement of ...

The most common types of cancer discovered through abdominal surgery are gastrointestinal, such as colon or stomach, genital or urinary, Dr. Ben Ho Park, director of precision oncology at ...